R&G PharmaStudies Co., Ltd. (SHE:301333)

R&G PharmaStudies Revenue

R&G PharmaStudies had revenue of 245.83M CNY in the quarter ending September 30, 2026, with 7.96% growth. This brings the company's total for the last twelve months to 957.42M, up 21.28% year-over-year. In the year 2025, R&G PharmaStudies had annual revenue of 851.01M with 14.38% growth. That makes R&G PharmaStudies the 19,959th largest company in the world by revenue and 3,662nd in China.

• Revenue (ttm): 957.42M
• Revenue Growth: +21.28%
• P/S Ratio: 5.82
• Revenue / Employee: 361.98K
• Employees: 2,645
• Market Cap: 5.58B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Clinical Trial Related and Laboratory Services 438.27M 51.5%
• Clinical Trial Technical Services 412.74M 48.5%

By Geography

Chart

• China 779.64M 91.6%
• Overseas 71.37M 8.4%

Fiscal year ended Dec 31, 2025 See the full R&G PharmaStudies breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	851.01M	107.00M	14.38%
Dec 31, 2024	744.00M	22.63M	3.14%
Dec 31, 2023	721.37M	83.85M	13.15%
Jan 1, 2023	637.52M	29.09M	4.78%
Jan 1, 2022	608.43M	123.98M	25.59%

Data Source: S&P Global Market Intelligence Last updated: Oct 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error